GLPwatch
Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake
NCT03141632 · Completed
Last updated 2026-05-28This clinical trial tests whether GLP-1 analogues affect fluid intake in people experiencing thirst or water-electrolyte imbalances.
Status Completed The study has finished.
Phase Phase 2 Tests whether it works and watches safety in a moderate group.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 17 people
Who can join Ages 18–65 · all sexes Healthy volunteers accepted.
Timeline Started 2016-10 · est. completion 2017-05
Where 1 site · Switzerland
What this study is testing ClinicalTrials.gov NCT03141632 ↗
Description as written by the study sponsor.
The aim of this study is to elucidate whether GLP-1 analogues influence not only appetite but also thirst perception. It is hypothesized that GLP-1 analogues reduce fluid intake in healthy volunteers compared to Placebo.
Treatments tested
- Dulaglutide also known as Verum Drug
Evaluation visit with assessment of fluid intake
- Placebo Other
Evaluation visit with assessment of fluid intake
| Main thing measured | Fluid intake |
|---|---|
| Sponsor | University Hospital, Basel, Switzerland |
| Conditions studied | Thirst, Water-Electrolyte Imbalance |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03141632 ↗